Compare Dishman Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUN PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUN PHARMA DISHMAN PHARMA/
SUN PHARMA
 
P/E (TTM) x 25.1 27.0 92.9% View Chart
P/BV x 3.3 2.3 143.5% View Chart
Dividend Yield % 0.7 0.7 97.0%  

Financials

 DISHMAN PHARMA   SUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUN PHARMA
Mar-19
DISHMAN PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs374679 55.2%   
Low Rs129375 34.3%   
Sales per share (Unadj.) Rs197.8121.1 163.3%  
Earnings per share (Unadj.) Rs21.213.4 158.5%  
Cash flow per share (Unadj.) Rs34.720.7 167.9%  
Dividends per share (Unadj.) Rs2.002.75 72.7%  
Dividend yield (eoy) %0.80.5 152.3%  
Book value per share (Unadj.) Rs179.9172.6 104.2%  
Shares outstanding (eoy) m80.692,399.26 3.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.4 29.2%   
Avg P/E ratio x11.939.4 30.1%  
P/CF ratio (eoy) x7.225.5 28.4%  
Price / Book Value ratio x1.43.1 45.8%  
Dividend payout %9.420.6 45.9%   
Avg Mkt Cap Rs m20,3061,264,650 1.6%   
No. of employees `0000.817.5 4.7%   
Total wages/salary Rs m5,35559,671 9.0%   
Avg. sales/employee Rs Th19,252.716,608.1 115.9%   
Avg. wages/employee Rs Th6,459.53,409.6 189.5%   
Avg. net profit/employee Rs Th2,064.11,833.8 112.6%   
INCOME DATA
Net Sales Rs m15,961290,659 5.5%  
Other income Rs m26510,255 2.6%   
Total revenues Rs m16,226300,914 5.4%   
Gross profit Rs m4,10363,076 6.5%  
Depreciation Rs m1,09117,533 6.2%   
Interest Rs m9445,553 17.0%   
Profit before tax Rs m2,33450,246 4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m6246,009 10.4%   
Profit after tax Rs m1,71132,093 5.3%  
Gross profit margin %25.721.7 118.5%  
Effective tax rate %26.712.0 223.5%   
Net profit margin %10.711.0 97.1%  
BALANCE SHEET DATA
Current assets Rs m11,018310,692 3.5%   
Current liabilities Rs m9,517173,396 5.5%   
Net working cap to sales %9.447.2 19.9%  
Current ratio x1.21.8 64.6%  
Inventory Days Days11099 111.6%  
Debtors Days Days35112 31.2%  
Net fixed assets Rs m16,304232,477 7.0%   
Share capital Rs m1612,399 6.7%   
"Free" reserves Rs m12,907411,691 3.1%   
Net worth Rs m14,516414,091 3.5%   
Long term debt Rs m4,18915,226 27.5%   
Total assets Rs m29,805646,938 4.6%  
Interest coverage x3.510.0 34.5%   
Debt to equity ratio x0.30 784.9%  
Sales to assets ratio x0.50.4 119.2%   
Return on assets %8.95.8 153.1%  
Return on equity %11.87.8 152.1%  
Return on capital %17.510.2 172.4%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95266,025 7.5%   
Fx outflow Rs m69738,610 1.8%   
Net fx Rs m4,25527,415 15.5%   
CASH FLOW
From Operations Rs m2,78621,965 12.7%  
From Investments Rs m-1,529-6,813 22.4%  
From Financial Activity Rs m-941-27,305 3.4%  
Net Cashflow Rs m316-8,442 -3.7%  

Share Holding

Indian Promoters % 61.4 63.7 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.1 72.1%  
FIIs % 12.7 23.0 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.3 266.3%  
Shareholders   46,261 133,026 34.8%  
Pledged promoter(s) holding % 35.8 0.5 6,747.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - FDC LTD. COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS